Methods and compositions related to platelet releasate and platelet-rich fibrin
AssigneeBiobridge Global
InventorAnand SRINIVASAN
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods comprising human platelet releasate (hPR), a xeno-free media supplement. The disclosure also relates to a cGMP process for the rapid, efficient and large-scale manufacturing of hPR that may be performed in less than 4 hours. The platelet releasate of the current disclosure prevents gelation of growth media alleviating the need for heparin or other anticoagulants. Mesenchymal stem cells expanded in the presence of platelet releasate have demonstrated superior expansion rates and potency compared to commercial supplements including platelet lysates. The releasate has therapeutic and medical applications. The disclosure also relates to compositions and methods related to platelet-rich fibrin.
Claims26
A method for preparing a platelet releasate, the method comprising the steps of:
- i) obtaining platelets from mammalian blood thereby obtaining platelet-rich-plasma (PRP);
- ii) adding a calcium salt or magnesium salt to the PRP to a final concentration of greater than 25 mM, thereby generating a salt/PRP mixture;
- and,
- iii) agitating the salt/PRP mixture for less than 6 hours thereby forming a clot and a releasate.
2-3. (canceled)
5-13. (canceled)
15-27. (canceled)
31-38. (canceled)
40-43. (canceled)
46-121. (canceled)
A method of treating a diseased or damaged tissue in a mammalian subject in need thereof comprising administering to the subject a therapeutic formulation comprising a releasate from mammalian blood-derived platelets, wherein the releasate comprises fibrinogen at a level of less than about 0.05 mg/dL.
A pharmaceutical formulation comprising a releasate from mammalian blood-derived platelets, the releasate comprising fibrinogen at a level of less than about 0.05 mg/dL, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.